Medivation Inc

Medivation — Investor Presentation (July 2016)

57 slides from Medivation's investor presentation, Jul 6, 2016

  1. Slide 1: Slide 1

  2. Slide 2: Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor

    Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor July 2016 Exhibit 99.1 WELCOME TO MEDIVATION

  3. Slide 3: Forward-Looking Statements

    2 Forward-Looking Statements Forward-looking statements are made throughout this presentation. The forward-looking statements in this presentation include, but are not limited to, estimates and other speculative statements regarding the potential for the PARP inhibitor class in general and talazopar

  4. Slide 4: Talazoparib: A Potentially Best-in-Class PARP Inhibitor (PARPi)

    Talazoparib: A Potentially Best-in-Class PARP Inhibitor (PARPi) 3 Differentiated Mechanism of Action Compelling Clinical Data Phase 3 Data Approaching Blockbuster Potential High Probability of Success Significantly greater potency in vitro and lowest clinical dose relative to other PARPi’s in clinic

  5. Slide 5: Talazoparib is Distinguished from Other PARP Inhibitors by Several Important Characteristics

    Talazoparib is Distinguished from Other PARP Inhibitors by Several Important Characteristics Talazoparib Appears to be the Most Optimized PARP Inhibitor in Development 4 Most potent PARP inhibitor reported Strongest tumor cell killing ability Highest efficiency at PARP trapping Highly selective for

  6. Slide 6: Introduction to Talazoparib

    Introduction to Talazoparib

  7. Slide 7: PARP Inhibitors Could be the Next Major Class of Therapeutics in Oncology

    PARP Inhibitors Could be the Next Major Class of Therapeutics in Oncology Recent Equity Research Highlight the Excitement of PARP Inhibitors 6 “PARP inhibitors may have broad applicability in cancer therapies beyond the initial indications in a subset of high- grade ovarian cancers.” - William Blair

  8. Slide 8: PARP Inhibitors Act Through Dual Cytotoxic Mechanisms

    PARP Inhibitors Act Through Dual Cytotoxic Mechanisms National Cancer Institute Research (Yves Pommier) 7 Talazoparib Source: Murai et al. Cancer Res 2012, 72(21) 5588-99; and Medivation. Mechanism 1: PARP Enzyme Inhibition Mechanism 2: PARP Trapping Cell death in DNA damage repair deficient cells (

  9. Slide 9: Mechanism 1: Inhibition of PARP Enzyme

    Mechanism 1: Inhibition of PARP Enzyme PARP Inhibitors Prevent DNA Damage Repair Leading to Tumor Cell Kill 8 Cancer cells replicate frequently and make many errors in DNA that require repair for survival PARP is the major DNA repair enzyme Tumors have many DNA repair defects, such as BRCA-mutations

  10. Slide 10: Mechanism 1: Talazoparib is the Most Potent Inhibitor of PARP Enzyme in Clinical Development

    9 Mechanism 1: Talazoparib is the Most Potent Inhibitor of PARP Enzyme in Clinical Development All PARP inhibitors inhibit PARP enzyme… Source: Shen et al. Clin Cancer Res 2013; 19:5003–15. Note: PARP inhibition represents relative concentration for 50% inhibition in PARP1 enzyme assay. Most Potent

  11. Slide 11: If Talazoparib is 3X–8X More Potent in PARP Inhibition, Why 2,000X Better at Killing Cancer Cells?

    10 If Talazoparib is 3X – 8X More Potent than Other PARP Inhibitors in PARP Inhibition, Why is it 2,000X Better at Killing Cancer Cells in Vitro? All PARP inhibitors inhibit PARP enzyme… …but potency of PARP enzyme inhibition does not correlate with antitumor activity… Source: Shen et al. Clin Cance

  12. Slide 12: Why is Talazoparib Orders of Magnitude More Potent than Olaparib in Xenograft Models?

    And Why is Talazoparib Orders of Magnitude More Potent than Olaparib in Cancer Xenograft Models? BRCA-Mutated Breast Cancer Xenograft Mouse Model 11 Talazoparib 0.1 mg/kg Talazoparib 0.33 mg/kg Olaparib 100 mg/kg Vehicle Source: Shen et al. Clin Cancer Res 2013; 19:5003–15. Note: MX-1 tumor xenograf

  13. Slide 13: Olaparib Maximally Inhibits PARP Enzyme Even at a Clinically Ineffective Dose

    Because PARP Enzyme Inhibition is Not Key: Olaparib Maximally Inhibits PARP Enzyme Even at 40 mg, a Dose That is Clinically Ineffective Current Olaparib Clinical Dose is 300-400mg BID 12 Source: Fong et al. NEJM 2009; 361: 123-134. Maximum PARP enzyme inhibition evidenced by virtual elimination of P

  14. Slide 14: Rucaparib Maximally Inhibits PARP Enzyme Even at a Clinically Ineffective Dose

    Because PARP Enzyme Inhibition is Not Key: Rucaparib Maximally Inhibits PARP Enzyme Even at 92 mg, a Dose That is Clinically Ineffective Current Rucaparib Clinical Dose is 600mg BID 13 Phase 2 multi-center trial investigating intermittent and continuous dosing schedules of rucaparib in germline BRCA

  15. Slide 15: Cancer Cell Cytotoxicity Correlates Better with PARP Trapping than Enzyme Inhibition

    All PARP inhibitors inhibit PARP enzyme… …but potency of PARP enzyme inhibition does not correlate with antitumor activity… …while PARP trapping ability is better correlated to antitumor activity Because Cancer Cell Cytotoxicity Correlates Better with PARP Trapping than PARP Enzyme Inhibition 14 Sou

  16. Slide 16: Mechanism 2: Talazoparib Traps PARP Protein on Single-Strand DNA Breaks

    Mechanism 2: Talazoparib, When Bound to PARP, Traps PARP Protein on Single-Strand DNA Breaks 15 PARP PARP PARP PARP Temozolomide Radiation Single-Strand DNA Breaks PARP Trapping Enhanced PARP-dependent cell killing Talazoparib Alkylation chemotherapies and radiation create single-strand DNA breaks w

  17. Slide 17: Publications Support PARP Trapping as a Better Correlate with Tumor Cell Killing

    Publications Support PARP Trapping as a Better Correlate with Tumor Cell Killing than PARP Inhibition PARP Inhibitors Differ Markedly in PARP Trapping Ability 16 “Trapped PARP–DNA complexes were more cytotoxic than…PARP inactivation” “a new mechanistic foundation for the rational application of PARP

  18. Slide 18: Talazoparib is the Most Potent and Niraparib the Second Most Potent PARP Trapper

    Talazoparib is the Most Potent and Niraparib is the Second Most Potent PARP Trapper in Clinical Development Slide 20, Yves Pommier, 13th International Congress on Targeted Anticancer Therapies, March 2015 17 Source: Pommier,13th International Congress on Targeted Anticancer Therapies (TAT 2015), Par

  19. Slide 19: Talazoparib is the Most Potent and Niraparib the Second Most Potent PARP Trapper

    Talazoparib is the Most Potent and Niraparib is the Second Most Potent PARP Trapper in Clinical Development 18 Niraparib is 2x more potent at PARP trapping than Olaparib Talazoparib is 100x more potent at PARP trapping than Olaparib Source: Murai et al, Cancer Res 2012; Murai et al, Molecular Cancer

  20. Slide 20: PARP Trapping Potency Correlates Better with Clinical Outcomes than Enzyme Inhibition

    PARP Trapping Potency Appears to Correlate Better with Clinical Outcomes than PARP Enzyme Inhibition Potency PARP Assays 1 Ovarian PFS 2 19 PARP-1 Enzyme Inhibition (IC50, nM) Cytotoxicity (IC90, nM) Relative PARP Trapping Activity BRCA- Mutated Patients Non-BRCA Mutated Patients Olaparib 4500 11.2

  21. Slide 21: Multi-Log Superiority of Talazoparib Over Olaparib in PARP Trapping Correlates with Non-HRD Cell Kill

    The Multi-Log Superiority of Talazoparib Over Olaparib in PARP Trapping Correlates with a Multi-Log Superiority in NON-HRD Cell Kill* 20 Prostate cancer PC-3 cells Ovarian cancer OvCAR3 cells (1) Cosmic database, Wellcome Trust Sanger Institute; CCLE database, Broad Institute. *These cell lines have

  22. Slide 22: Niraparib, a More Potent PARP Trapper than Olaparib, Resulted in Longer PFS

    Niraparib, a More Potent PARP Trapper than Olaparib, Resulted in Longer PFS than Olaparib 21 N IRAPARIB (NOVA) O LAPARIB Sponsor Tesaro AstraZeneca Trial Phase 3 ovarian cancer trial Phase 2 ovarian cancer trial Setting Maintenance following response to platinum in recurrent ovarian cancer Maintenan

  23. Slide 23: Low-Dose Chemo Can Further Amplify Talazoparib's Superior PARP Trapping

    22 Single-Strand DNA Breakers (e.g., Low-Dose Chemo) Can FURTHER Amplify Talazoparib’s Superior PARP Trapping Potentially Registrational Studies to Evaluate Combination to Begin by YE 2016 Source: Medivation. Note: NCI-H209 SCLC xenograft model. Talazoparib and temozolomide were administered orally,

  24. Slide 24: Low-Dose Radiation Can Further Amplify Talazoparib's Superior PARP Trapping

    Single-Strand DNA Breakers (e.g., Low-Dose Radiation) Can FURTHER Amplify Talazoparib’s Superior PARP Trapping 23 Enhancement of Head and Neck Cancer Cell Kill with Talazoparib in Combination with Low-Dose Radiation Source: Wong et al. Potent anti-tumor activity of talazoparib (BMN673) in combinatio

  25. Slide 25: Talazoparib is the Most Specific PARP Inhibitor for PARP1 and PARP2

    Talazoparib is the Most Specific PARP Inhibitor for PARP1 and PARP2 in Clinical Development PARP1 and PARP2 are the PARP Isoforms Used Most by Cancers 24 Specificity: Talazoparib > Veliparib > Olaparib > Rucaparib Source: Poster presented by Herwig Schuler at the 2014 PARP meeting. Wahlberg et al. N

  26. Slide 26: Talazoparib is Highly Specific and has Lower Off-Target Cell Toxicity

    Talazoparib is a Highly Specific PARP Inhibitor and has Lower Off-Target Cell Toxicity Cell Viability Assay in PARP1/2 Deficient Cells 25 Source: Murai et al. Mol Cancer Ther 2014, (2): 433–443. Note: DT40 PARP1-/- avian B lymphoblast cells used are equivalent to PARP1 and PARP2 double knockout cell

  27. Slide 27: Talazoparib's Cell Killing Effects are More PARP-Specific than Niraparib

    Talazoparib’s Cell Killing Effects are More PARP-Specific than Niraparib in TK6 Human Lymphoblastoid Cells 26 T ALAZOPARIB N IRAPARIB A cell line lacking PARP1 suffers little toxicity from Talazoparib at clinically effective doses Source: Pommier lab, NCI, unpublished data.

  28. Slide 28: Third-Party Comparison of Adverse Event Profile of Talazoparib vs. Other PARP Inhibitors

    Third-Party Comparison of Adverse Event Profile of Talazoparib vs. Other PARP Inhibitors 12% 4% 5% 33% 30% 23% 25% 16% 10% 16% 59% 35% 21% 26% 17% 16% 53% 17% 2% 1% 6% 47% 25% 24% 15% 56% 25% 36% 27% 49% 13% 11% 15% 5% 2% 2% 2% 5% 10% 59% 20% 28% 26% 16% 36% 43% 19% 4% 2% 1% 2% 1% 6% 30% 7% 27 Talaz

  29. Slide 29: Slide 29

  30. Slide 30: Slide 30

  31. Slide 31: Slide 31

  32. Slide 32: Clinical Data and Development Plans

    Clinical Data and Development Plans

  33. Slide 33: Talazoparib Will Be Tested Across Multiple Solid Tumor Indications

    Talazoparib Will Be Tested Across Multiple Solid Tumor Indications Current Talazoparib Clinical Development Plan 29 Phase 1 Phase 2 Phase 3 Breast Cancer (Germline BRCA-Mutation) (EMBRACA) Prostate Cancer (Monotherapy, Genetically-selected) Prostate Cancer (Monotherapy & Low-dose Combo Chemo, All-co

  34. Slide 34: Medivation

    MEDIVATION

  35. Slide 35: Talazoparib Studied in a Phase 1 Trial as Monotherapy in BRCA-Mutated Cancer Patients

    Talazoparib was Studied in a Phase 1 Trial as a Monotherapy in BRCA-Mutated Cancer Patients Evaluated 46 Germline BRCA-Mutated Breast and Ovarian Cancer Patients 31 Note: Asterisk indicates Talazoparib. Safety and Antitumor Activity of the PARP inhibitor BMN 673 * in a Phase 1 Trial Recruiting Metas

  36. Slide 36: Talazoparib Demonstrated Compelling Activity in BRCA-Mutated Breast Cancer Patients

    Talazoparib Demonstrated Compelling Activity in BRCA- Mutated Breast Cancer Patients RECIST Response in Germline BRCA-Mutated Breast Cancer 32 Genetic Status N CR PR SD <24 weeks or PD RECIST Response SD 24 weeks At the 1 mg/day Phase 3 dose: 7/14 had an objective response ( ORR = 50% ) 12/14 had a

  37. Slide 37: Talazoparib Demonstrated Strong Objective Responses in BRCA-Mutated Breast Cancer Patients

    Talazoparib Demonstrated Strong Objective Responses in BRCA-Mutated Breast Cancer Patients BRCA-Mutated Breast Cancer RECIST Response Waterfall Plot 33 Kaplan-Meier Estimates: Median duration of response: 32.0 weeks 95% C.I.: 19.9 – 40.3 weeks Median progression-free survival: 32.1 weeks 95% C.I. 13

  38. Slide 38: Third-Party Analysis of PARP Inhibitors in BRCAm Breast Cancer

    Third-Party Analysis of PARP Inhibitors in BRCAm Breast Cancer Supports Talazoparib’s Best-In-Class Potential Comparison of Single-Agent Activity in BRCA-Mutated Breast Cancer 34 Olaparib Niraparib Talazoparib Phase 2 Breast POC Phase 2 Phase 1/2 Phase 1 Source: Barclays Research; Kaye et al. J Clin

  39. Slide 39: EMBRACA: Talazoparib Phase 3 Study in gBRCA-Mutated Metastatic Breast Cancer is Ongoing

    EMBRACA: Talazoparib Phase 3 Study in Germline BRCA- Mutated Metastatic Breast Cancer is Ongoing 35 Note: Enrollment Initiated in October 2013. Compare PFS of patients treated with monotherapy talazoparib relative to those treated with protocol-specified physician’s choice single-agent chemotherapy

  40. Slide 40: Phase 3 EMBRACA is Similar to Competitors' Trials, but More Conservatively Designed

    Phase 3 EMBRACA is Similar to Competitors’ Trials, but More Conservatively Designed and Higher-Powered Comparison of Phase 3 BRCA-Mutated Breast Cancer Trial Designs 36 BRAVO (Niraparib) OlympiAD (Olaparib) EMBRACA (Talazoparib) Sponsor Tesaro AstraZeneca Medivation Phase 3 Dose Same as Phase 2 Dose

  41. Slide 41: Talazoparib is Being Studied in a Phase 2 Trial for Breast Cancer Beyond BRCA-Mutation

    Talazoparib is Being Studied in a Phase 2 Trial for the Treatment of Breast Cancer Beyond BRCA-Mutation 37 "The I-SPY 2 TRIAL is designed to rapidly test promising agents to reduce the cost, time and number of patients needed to bring new therapies to breast cancer patients who urgently need new tre

  42. Slide 42: Talazoparib: The Leading Prostate Cancer PARPi Program

    Talazoparib: The Leading Prostate Cancer PARPi Program M ONO - THERAPY S TUDY C HEMO - C OMBINATION S TUDY D ESIGN O UR O PPORTUNITY R ATIONALE 38 Single-arm study in post- NHT / post-chemotherapy mCRPC patients Patients selected for DNA repair defects Alignment on trial design with FDA reached, pot

  43. Slide 43: Investigator-Initiated Study of a PARPi in Advanced Prostate Cancer

    Investigator-Initiated Study of a PARPi in Advanced Prostate Cancer 39 The TOPARP Study Demonstrated the Potential of PARP Inhibitors in the Treatment of Prostate Cancer Source: Mateo et al. N Engl J Med 2015 Oct 29; 373(18):1697-708. Study: A Phase 2 Trial of Olaparib in Patients With Advanced Cast

  44. Slide 44: Data from TOPARP Study with PARPi in Advanced Prostate Cancer

    Data from TOPARP Study with PARPi in Advanced Prostate Cancer Prior lines of treatment n (%) 40 Striking Effects were Observed in Heavily Pre-treated, Advanced Metastatic Prostate Cancer Patients Patients dosed Evaluable for response Docetaxel 50 (100%) Cabazitaxel 29 (58%) Zytiga (abiraterone) 48 (

  45. Slide 45: Strong Activity Occurred in Most Patients with DNA Repair Defects

    Strong Activity Occurred in Most Patients with DNA Repair Defects 41 PARP Inhibition Even More Effective in Patients with HRD in TOPARP 16/49 (33%) of patients were identified as having DNA-repair defects Of these 16 patients, 14 patients had a response (88%) All 8 patients with a BRCA1 or BRCA2 los

  46. Slide 46: Radiologic Progression-Free Survival: Biomarker+ vs. Biomarker-

    Radiologic Progression-Free Survival: Biomarker+ vs. Biomarker- 42 PARP Inhibition Even More Effective in Patients with HRD in TOPARP Hazard Ratio: 0.24 (95% CI, 0.11 – 0.50) Source: Mateo et al. N Engl J Med 2015 Oct 29; 373(18):1697-708.

  47. Slide 47: Selected Talazoparib Preclinical Prostate Cancer Data

    Selected Talazoparib Preclinical Prostate Cancer Data 43 Talazoparib’s Potency and PARP Trapping Ability Could Make It Best in Class for the Treatment of Prostate Cancer Source: Medivation, unpublished data. Note: Monotherapy study in LNCaP cells, which are patient-derived prostate cancer cell line

  48. Slide 48: Low-Dose Temozolomide Potentiates Talazoparib in Prostate Cancer Cells

    Low-Dose Temozolomide Potentiates the Anti-tumor Effects of Sub-Maximal Talazoparib Doses in Prostate Cancer Cells Talazoparib Single-Agent Low-Dose Talazoparib with Temozolomide 44 Concentration tested for temozolomide potentiation Source: Medivation, unpublished data. Note: Temozolomide combinatio

  49. Slide 49: Talazoparib: The Leading Small Cell Lung Cancer PARPi Program

    Talazoparib: The Leading Small Cell Lung Cancer (SCLC) PARPi Program 1L M AINTENANCE S TUDY D ESIGN O UR O PPORTUNITY R ATIONALE 45 Phase 3 maintenance study after first-line chemotherapy Monotherapy and in combination with low-dose temozolomide Alignment with FDA reached Potentially first registrat

  50. Slide 50: Talazoparib Single-Agent Activity in Previously-Treated Small Cell Lung Cancer

    46 Talazoparib Demonstrated Single-Agent Activity in Patients with Advanced Previously-Treated Small Cell Lung Cancer Small Cell Lung Cancer RECIST Response Waterfall Plot Source: Wainberg et al. ASCO 2014, and Medivation. -75 -50 -25 Dose (mg/day) 1.0 Kaplan-Meier Estimates: Median duration of resp

  51. Slide 51: Talazoparib Synergizes with Low-Dose Temozolomide in SCLC Animal Model

    Talazoparib’s PARP Trapping Activity Synergizes Effectively with Low-Dose Temozolomide in SCLC Animal Model 47 Vehicle Temozolomide Talazoparib Talazoparib + Temozolomide Source: Medivation. Note: NCI-H209 SCLC xenograft model. Talazoparib and temozolomide were administered orally, once daily for 4

  52. Slide 52: Talazoparib: Exploiting PARP Trapping in Ovarian Cancer

    Talazoparib: Exploiting PARP Trapping in Ovarian Cancer PARP- F AILURE & PARP- S ENSITIVE S TUDY D ESIGN O UR O PPORTUNITY R ATIONALE 48 Potentially registrational study with multiple arms testing monotherapy and combination low-dose chemotherapy in both PARP-sensitive and PARP-failure patients Pote

  53. Slide 53: Talazoparib Demonstrated Compelling Activity in BRCA-Mutated Ovarian Cancer Patients

    Talazoparib Demonstrated Compelling Activity in BRCA- Mutated Ovarian Cancer Patients RECIST Response in Germline BRCA-Mutated Ovarian Cancer 49 Deleterious Mutation N Response CR/PR SD > 24 weeks SD < 24 weeks/PD RECIST (1) CA-125 (2) Clinical benefit response rate (CR, PR, SD 24 weeks): 23/28 ( CB

  54. Slide 54: Talazoparib Compelling Activity in BRCA-Mutated Ovarian Cancer Patients (continued)

    Talazoparib Demonstrated Compelling Activity in BRCA- Mutated Ovarian Cancer Patients ( c ontinued) BRCA-Mutated Ovarian Cancer RECIST Response Waterfall Plot 50 Source: Wainberg et al. ASCO 2014. Note: Asterisks indicate treatment ongoing at the time of data cutoff (April 18, 2014). Kaplan-Meier Es

  55. Slide 55: Talazoparib Plus Low-Dose Chemotherapy Clinical Data (AACR 2016)

    Talazoparib Plus Low-Dose Chemotherapy Clinical Data (AACR 2016) 51 Superior PARP Trapping May Lead to Improved Clinical Outcomes in Broad Patient Populations as Seen in Ovarian Cancer Talazoparib is active in tumors with defects in DNA repair genes beyond BRCA-mutations (larger market than BRCA) an

  56. Slide 56: Talazoparib Investigator-Sponsored Trials

    Talazoparib Investigator-Sponsored Trials 52 Talazoparib is Being Further Explored Across Indications through Several Investigator-Sponsored Studies Investigator Institution Phase Indication Other Wainberg UCLA Phase 1 Advanced solid tumors Combination with irinotecan or temozolomide Piha-Paul MD An

  57. Slide 57: Multiple Indications to Pursue as Monotherapy or Combination Therapy

    Multiple Indications to Pursue as Monotherapy or Combination Therapy 53 Talazoparib Holds the Potential to Address Multiple Tumor Types and a Large Commercial Opportunity 140k 80k 100k 140k 60k 230k Potential Addressable Patient Population (U.S. and Europe) Phase Potential Launch 2022-23 2022-23 P2

Medivation — Investor Presentation (July 2016) on 6ix